M6A RNA methylation in biliary tract cancer: the function roles and potential therapeutic implications

[1]  Yue Huang,et al.  Chemical Inhibitors Targeting the Oncogenic m6A Modifying Proteins. , 2023, Accounts of chemical research.

[2]  Shengnan Zhou,et al.  YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A‐dependent DAPK3 degradation , 2023, Cancer science.

[3]  Zhi-hang Chen,et al.  METTL5-mediated 18S rRNA m6A modification promotes oncogenic mRNA translation and intrahepatic cholangiocarcinoma progression. , 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Meng-Xin Tian,et al.  Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy , 2023, Oncogene.

[5]  Ligong Lu,et al.  VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization , 2023, Journal of Gastroenterology.

[6]  Zhe S Chen,et al.  Epigenetic modification of m6A regulator proteins in cancer , 2023, Molecular Cancer.

[7]  Dan Tao,et al.  The role of m6A methylation in therapy resistance in cancer , 2023, Molecular Cancer.

[8]  Yue Huang,et al.  METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation , 2023, Cell Death & Disease.

[9]  W. Dong,et al.  m6A RNA methylation-mediated upregulation of HLF promotes intrahepatic cholangiocarcinoma progression by regulating the FZD4/β-catenin signaling pathway. , 2023, Cancer letters.

[10]  Jieke Cui,et al.  Alternative splicing of HOXB-AS3 underlie the promoting effect of nuclear m6A reader YTHDC1 on the self-renewal of leukemic stem cells in acute myeloid leukemia. , 2023, International journal of biological macromolecules.

[11]  Lu Zhao,et al.  m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion , 2023, Molecular Cancer.

[12]  Guanqun Li,et al.  IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression. , 2023, Cancer letters.

[13]  Yue Zhao,et al.  CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m6A) modification , 2023, Journal of Translational Medicine.

[14]  Qin Dang,et al.  Biological and pharmacological roles of m6A modifications in cancer drug resistance , 2022, Molecular cancer.

[15]  Hai Hu,et al.  METTL3 promotes glycolysis and cholangiocarcinoma progression by mediating the m6A modification of AKR1B10 , 2022, Cancer Cell International.

[16]  Junzhe Zhang,et al.  IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N6-methyladenosine-dependent binding , 2022, Frontiers in Oncology.

[17]  Y. Wang,et al.  CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma , 2022, Molecular cancer.

[18]  Yang Yang,et al.  Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer , 2022, Journal of enzyme inhibition and medicinal chemistry.

[19]  Jun Lu,et al.  Potential prognosis index for m6A-related mRNA in cholangiocarcinoma , 2022, BMC Cancer.

[20]  Hongbing Shen,et al.  The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers , 2022, Nature Communications.

[21]  Wei Zhao,et al.  YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation , 2022, Clinical and translational medicine.

[22]  Hui Chen,et al.  Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer , 2022, Frontiers in Oncology.

[23]  P. Yi,et al.  Targeting the RNA m6A modification for cancer immunotherapy , 2022, Molecular cancer.

[24]  Xinjian Wan,et al.  m5C and m6A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axis , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[25]  Lixia Xu,et al.  YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation , 2022, Journal of gastroenterology and hepatology.

[26]  Xianbiao Xie,et al.  M6A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes Wnt signaling to facilitate osteosarcoma progression , 2022, Oncogene.

[27]  Wei Zhao,et al.  METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner , 2022, Oncogene.

[28]  Jing Liu,et al.  Insights into N6-methyladenosine and programmed cell death in cancer , 2022, Molecular cancer.

[29]  L. Ouyang,et al.  Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity , 2022, Frontiers in Immunology.

[30]  Yuanyuan An,et al.  The role of m6A RNA methylation in cancer metabolism , 2022, Molecular cancer.

[31]  L. Pang,et al.  Detailed resume of RNA m6A demethylases , 2022, Acta pharmaceutica Sinica. B.

[32]  Christine C. Hudson,et al.  Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. , 2021, Cancer discovery.

[33]  Peng Gao,et al.  METTL3-mediated N6-methyladenosine modification of DUSP5 mRNA promotes gallbladder-cancer progression , 2021, Cancer Gene Therapy.

[34]  R. Shroff,et al.  Current and emerging therapies for advanced biliary tract cancers. , 2021, The lancet. Gastroenterology & hepatology.

[35]  S. Ji,et al.  The m6A Readers YTHDF1 and YTHDF2 Synergistically Control Cerebellar Parallel Fiber Growth by Regulating Local Translation of the Key Wnt5a Signaling Components in Axons , 2021, Advanced science.

[36]  Wentao Wang,et al.  The m6A writers regulated by the IL-6/STAT3 inflammatory pathway facilitate cancer cell stemness in cholangiocarcinoma , 2021, Cancer biology & medicine.

[37]  Jiawang Zhou,et al.  A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities , 2021, Acta pharmaceutica Sinica. B.

[38]  Hong-Yang Wang,et al.  M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma , 2021, Cancer Research.

[39]  S. Yeh,et al.  R-2HG downregulates ERα to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERα/miR16-5p/YAP1 signal pathway , 2021, Molecular therapy oncolytics.

[40]  Yue Huang,et al.  Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. , 2021, Cell metabolism.

[41]  Guodong Sun,et al.  ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer , 2021, Journal of experimental & clinical cancer research : CR.

[42]  Siyuan Lin,et al.  The RNA m6A reader YTHDC1 silences retrotransposons and guards ES cell identity , 2021, Nature.

[43]  Guohui Wan,et al.  Methyladenosine Modification in RNAs: Classification and Roles in Gastrointestinal Cancers , 2021, Frontiers in Oncology.

[44]  T. Rana,et al.  m6A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells , 2021, ACS chemical biology.

[45]  D. Pei,et al.  N6‐methyladenosine (m6A) RNA modification in human cancer , 2020, Cell proliferation.

[46]  Qinfeng Xu,et al.  Identification of Specific N6-methyladenosine RNA Demethylase FTO Inhibitors by Single Quantum Dot-Based FRET Nanosensor. , 2020, Analytical chemistry.

[47]  Y. Assaraf,et al.  Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[48]  Songshan Jiang,et al.  FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma , 2020, Cancer Research.

[49]  Jian-xiong Ma,et al.  Photoactivatable RNA N6 -Methyladenosine Editing with CRISPR-Cas13. , 2020, Small.

[50]  Hui Shen,et al.  Deoxycholic acid modulates the progression of gallbladder cancer through N6-methyladenosine-dependent microRNA maturation , 2020, Oncogene.

[51]  David R. Liu,et al.  Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase , 2020, Nature Biotechnology.

[52]  Yue Huang,et al.  Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. , 2020, Cancer cell.

[53]  B. Zhang,et al.  m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer , 2020, Molecular Cancer.

[54]  Jianjun Chen,et al.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. , 2020, Cancer cell.

[55]  Shiqing Ma,et al.  METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification , 2020, Molecular therapy. Nucleic acids.

[56]  Jianjun Chen,et al.  The Biogenesis and Precise Control of RNA m6A Methylation. , 2019, Trends in genetics : TIG.

[57]  Joshua D. Campbell,et al.  Genomic and immune profiling of pre-invasive lung adenocarcinoma , 2019, Nature Communications.

[58]  Shu-Bing Qian,et al.  m6A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2 , 2019, Nature Communications.

[59]  I. Mills,et al.  The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing , 2019, Cancers.

[60]  Yi-di Guan,et al.  Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma , 2019, Front. Oncol..

[61]  Ok Hyun Park,et al.  Endoribonucleolytic Cleavage of m6A-Containing RNAs by RNase P/MRP Complex. , 2019, Molecular cell.

[62]  Chuan He,et al.  Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. , 2019, Molecular cell.

[63]  C. Chiang,et al.  Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein , 2019, bioRxiv.

[64]  Yanli Wang,et al.  Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1 , 2019, Science Translational Medicine.

[65]  Hualiang Jiang,et al.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. , 2019, Cancer cell.

[66]  Xuetao Cao,et al.  CCR7 Chemokine Receptor‐Inducible lnc‐Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF‐1&agr;‐Mediated Glycolysis , 2019, Immunity.

[67]  R. Weichselbaum,et al.  Anti-tumor immunity controlled through mRNA m6A and YTHDF1 in dendritic cells , 2019, Nature.

[68]  Junbiao Chang,et al.  Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity. , 2019, Chemico-biological interactions.

[69]  Zhike Lu,et al.  Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. , 2018, Molecular cell.

[70]  J. Chai,et al.  Identification of Natural Compound Radicicol as a Potent FTO Inhibitor. , 2018, Molecular pharmaceutics.

[71]  Hui-Lung Sun,et al.  Link Between m6A Modification and Cancers , 2018, Front. Bioeng. Biotechnol..

[72]  Yu-Sheng Chen,et al.  Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism , 2018, Cell Research.

[73]  Yang Shi,et al.  Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal. , 2018, Molecular cell.

[74]  Mark Helm,et al.  Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m6A machinery component Wtap/Fl(2)d , 2018, Genes & development.

[75]  Stefan Hüttelmaier,et al.  Recognition of RNA N6-methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation , 2018, Nature Cell Biology.

[76]  James E. Bradner,et al.  R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling , 2018, Cell.

[77]  Howard Y. Chang,et al.  m6A mRNA methylation sustains Treg suppressive functions , 2018, Cell Research.

[78]  Tsutomu Suzuki,et al.  S-Adenosylmethionine Synthesis Is Regulated by Selective N6-Adenosine Methylation and mRNA Degradation Involving METTL16 and YTHDC1. , 2017, Cell reports.

[79]  Ravi Sachidanandam,et al.  Regulation of m6A Transcripts by the 3'→5' RNA Helicase YTHDC2 Is Essential for a Successful Meiotic Program in the Mammalian Germline. , 2017, Molecular cell.

[80]  Chuan He,et al.  YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs , 2017, eLife.

[81]  Peng Nie,et al.  m6AVar: a database of functional variants involved in m6A modification , 2017, Nucleic Acids Res..

[82]  Xiu-Jie Wang,et al.  Mettl3-mediated m6A regulates spermatogonial differentiation and meiosis initiation , 2017, Cell Research.

[83]  Yuval Kluger,et al.  m6A mRNA methylation controls T cell homeostasis by targeting IL-7/STAT5/SOCS pathway , 2017, Nature.

[84]  Wei Yan,et al.  MicroRNAs control mRNA fate by compartmentalization based on 3′ UTR length in male germ cells , 2017, Genome Biology.

[85]  Zefeng Wang,et al.  Autoregulation of RBM10 and cross-regulation of RBM10/RBM5 via alternative splicing-coupled nonsense-mediated decay , 2017, Nucleic acids research.

[86]  Yang Xie,et al.  The U6 snRNA m6A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention , 2017, Cell.

[87]  Zhike Lu,et al.  m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells , 2017, Cell reports.

[88]  K. Harada,et al.  AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells , 2017, Scientific Reports.

[89]  Chuan He,et al.  YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA , 2017, Cell Research.

[90]  Olivier Elemento,et al.  Reversible methylation of m6Am in the 5′ cap controls mRNA stability , 2016, Nature.

[91]  Ligang Wu,et al.  YTHDF2 destabilizes m6A-containing RNA through direct recruitment of the CCR4–NOT deadenylase complex , 2016, Nature Communications.

[92]  Ping Wang,et al.  Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. , 2016, Molecular cell.

[93]  A. Lucci,et al.  Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge , 2016, PloS one.

[94]  P. Dedon,et al.  m6A-LAIC-seq reveals the census and complexity of the m6A epitranscriptome , 2016, Nature Methods.

[95]  J. Massagué,et al.  Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer , 2016, Nature.

[96]  Samir Adhikari,et al.  Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. , 2016, Molecular cell.

[97]  Rong Wang,et al.  Coordination of m(6)A mRNA Methylation and Gene Transcription by ZFP217 Regulates Pluripotency and Reprogramming. , 2015, Cell stem cell.

[98]  Olivier Elemento,et al.  5′ UTR m6A Promotes Cap-Independent Translation , 2015, Cell.

[99]  Tianlu Wang,et al.  Fluorescein Derivatives as Bifunctional Molecules for the Simultaneous Inhibiting and Labeling of FTO Protein. , 2015, Journal of the American Chemical Society.

[100]  Christopher E. Mason,et al.  Single-nucleotide resolution mapping of m6A and m6Am throughout the transcriptome , 2015, Nature Methods.

[101]  Chuan He,et al.  N 6 -methyladenosine Modulates Messenger RNA Translation Efficiency , 2015, Cell.

[102]  M. Ares,et al.  Context-dependent control of alternative splicing by RNA-binding proteins , 2014, Nature Reviews Genetics.

[103]  Neville E. Sanjana,et al.  Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. , 2014, Cell reports.

[104]  Samir Adhikari,et al.  Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase , 2014, Cell Research.

[105]  Yang Wang,et al.  N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells , 2014, Nature Cell Biology.

[106]  Zhike Lu,et al.  m6A-dependent regulation of messenger RNA stability , 2013, Nature.

[107]  Zhike Lu,et al.  ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. , 2013, Molecular cell.

[108]  Cheng Luo,et al.  Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. , 2012, Journal of the American Chemical Society.

[109]  O. Elemento,et al.  Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons , 2012, Cell.

[110]  T. Roskams,et al.  Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes , 2012, Hepatology.

[111]  M. Kupiec,et al.  Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq , 2012, Nature.

[112]  J. Auwerx,et al.  The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. , 2011, Journal of hepatology.

[113]  J. Kaprio,et al.  Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins. , 2009, European journal of cancer.

[114]  A. Willis,et al.  Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression , 2004, Oncogene.

[115]  Hailing,et al.  Differential m 6 A, m 6 A m , and m 1 A Demethylation Mediated by FTO in Cell Nucleus and Cytoplasm , 2018 .

[116]  S. Curley,et al.  Biliary tract cancer. , 1997, Cancer treatment and research.